Cambridge, MA, United States of America

Brendan Bulik-Sullivan

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 3.8

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2018-2024

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovative Mind of Brendan Bulik-Sullivan: Pioneering Neoantigen Research

Introduction: Brendan Bulik-Sullivan, based in Cambridge, MA, is an accomplished inventor with a remarkable portfolio of six patents. His groundbreaking work primarily focuses on the intricate field of neoantigens, providing valuable advancements in cancer immunotherapy.

Latest Patents: Among Brendan's notable patents is the method for “Reducing junction epitope presentation for neoantigens.” This innovation involves designing a cassette sequence that minimizes the risk of junction epitopes being presented in patients, by employing distance metrics to assess presentation likelihood. Another significant patent is for “Neoantigen identification using hotspots,” which describes a method for pinpointing neoantigens likely to appear on tumor cell surfaces. By utilizing machine learning, this approach analyzes peptide sequences derived from tumor cells, leading to informed selection of neoantigens based on their presentation likelihoods.

Career Highlights: Brendan has made significant contributions to cancer treatment through his roles at leading organizations such as Gritstone Oncology, Inc. and Gritstone Bio, Inc. His work at these institutions underscores his commitment to advancing cancer therapeutics and enhancing patient outcomes through innovative science.

Collaborations: Throughout his career, Brendan has collaborated with esteemed professionals in his field, including Roman Yelensky and Jennifer Busby. These partnerships have fostered an environment of innovation and shared expertise, further propelling advancements in neoantigen research.

Conclusion: Brendan Bulik-Sullivan continues to be a prominent figure in the realm of cancer immunotherapy through his innovative patents and collaborative efforts. His work not only signifies a leap forward in understanding neoantigens but also reinforces the importance of innovation in developing effective cancer treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…